Cargando…
Neoadjuvant Immunotherapy Improves Treatment for Early Resectable Non-Small-Cell Lung Cancer: A Systematic Review and Meta-analysis
OBJECTIVE: Immunotherapy has shown better efficacy and less toxicity than chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) at advanced stage. This study evaluates the safety and efficacy of neoadjuvant immunotherapy for resectable NSCLC. METHODS: Literature examination was perform...
Autores principales: | Dong, Peng, Yan, Yu, Yang, Liyuan, Wu, Danzhu, Wang, Hui, Lv, Yajuan, Zhang, Jiandong, Yu, Xinshuang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546650/ https://www.ncbi.nlm.nih.gov/pubmed/36213828 http://dx.doi.org/10.1155/2022/2085267 |
Ejemplares similares
-
The Role of Myeloid-Derived Suppressor Cells in the Treatment of Pancreatic Cancer
por: Dong, Peng, et al.
Publicado: (2022) -
Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer
por: Cao, Christopher, et al.
Publicado: (2021) -
Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
por: Chen, Lanyi Nora, et al.
Publicado: (2023) -
The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
por: Jiang, Long, et al.
Publicado: (2021) -
Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpoint
por: Faltermeier, Claire M., et al.
Publicado: (2021)